<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Probenecid: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Probenecid: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Probenecid: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9812" href="/d/html/9812.html" rel="external">see "Probenecid: Drug information"</a> and <a class="drug drug_patient" data-topicid="11841" href="/d/html/11841.html" rel="external">see "Probenecid: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1061363"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adjuvant Therapy, Penicillin Level Prolongation</span>;</li>
<li>
<span class="list-set-name">Antigout Agent</span>;</li>
<li>
<span class="list-set-name">Uric Acid Lowering Agent</span>;</li>
<li>
<span class="list-set-name">Uricosuric Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F213428"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13c00399-e2c1-4bbd-a4e9-7be1bd050d85">Prolongation of penicillin serum levels</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prolongation of penicillin serum levels:</b> Children ≥2 years and Adolescents: <b>Note:</b> Dosing for some indication-specific dosing may vary.</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight ≤50 kg: Oral: Initial: 25 mg/kg/dose or 700 mg/<b>m<sup>2</sup></b>/dose as a single dose; maintenance: 40 mg/kg/<b>day</b> or 1,200 mg /<b>m<sup>2</sup>/day</b> in 4 divided doses; maximum dose: 500 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Patient weight &gt;50 kg: Oral: 500 mg 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce924d2e-bbcf-416d-96a3-5be453cecbcd">Gonorrhea, uncomplicated infections of cervix, urethra, and rectum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonorrhea, uncomplicated infections of cervix, urethra, and rectum:</b> Adolescents &gt;45 kg: Oral: 1,000 mg as a single dose with cefoxitin; <b>Note</b>: Combination of ceftriaxone and azithromycin is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease:</b> Adolescents: Oral: 1,000 mg as a single dose with cefoxitin in combination with doxycycline with/without metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4cfe0ef-74fa-41a0-8f2e-b1f919adbbb4">Neurosyphilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurosyphilis:</b> Adolescents: Oral: 500 mg 4 times daily with procaine penicillin for 10 to 14 days; alternative therapy to aqueous penicillin G therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26042815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26042815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd2d3b66-4540-42e6-a010-cdc6643676b5">Cidofovir nephrotoxicity, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cidofovir</b>
<b> nephrotoxicity, prevention:</b> Limited data available; various regimens have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18307672','lexi-content-ref-19392729','lexi-content-ref-16157264','lexi-content-ref-17845926','lexi-content-ref-19801951','lexi-content-ref-16732176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18307672','lexi-content-ref-19392729','lexi-content-ref-16157264','lexi-content-ref-17845926','lexi-content-ref-19801951','lexi-content-ref-16732176'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:<b> Note: </b>The manufacturer's labeling considers use in patients &lt;2 years of age to be contraindicated; however, clinical studies have included younger ages (including infants) for this indication.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">BSA-based dosing: Oral: 1,000 or 1,250 mg/<b>m<sup>2</sup></b>/dose administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/<b>m<sup>2</sup></b>/dose 1 to 2 hours and 8 hours after completion.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51154965"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: CrCl &lt;30 mL/minute: Avoid use (reduced efficacy with renal impairment).</p></div>
<div class="block dohp drugH1Div" id="F51154966"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F213413"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9812" href="/d/html/9812.html" rel="external">see "Probenecid: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd2d3b66-4540-42e6-a010-cdc6643676b5">Cidofovir nephrotoxicity, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cidofovir nephrotoxicity, prevention (off-label use): Oral:</b> 2 g as a single dose administered 3 hours before cidofovir infusion, followed by 1 g at 2 hours and 8 hours after cidofovir infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-hhs.1','lexi-content-ref-9502489','lexi-content-ref-30403300','lexi-content-ref-Vistide.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-hhs.1','lexi-content-ref-9502489','lexi-content-ref-30403300','lexi-content-ref-Vistide.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6c554230-de9b-4de2-bcaf-af813baf0c2c">Hyperuricemia, gout prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperuricemia, gout prevention (alternative agent):</b>
<b>Oral:</b> 250 mg twice daily for 1 week, followed by 500 mg twice daily; may increase dose by 500 mg every 4 weeks as tolerated if symptoms are not controlled; usual maintenance dose: ≤2 g/day in divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="30981a02-bc5d-4aeb-843c-2f2a708e5c09">Sexually transmitted infections, as a pharmacokinetic enhancer to prolong beta-lactam serum levels</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections, as a pharmacokinetic enhancer to prolong beta-lactam serum levels (adjunctive agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gonococcal infection, uncomplicated:</i>
<b>Oral:</b> 1 g as a single dose in combination with single-dose IM cefoxitin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurosyphilis, including ocular and otosyphilis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve for patients unable to receive IV therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg 4 times daily in combination with IM procaine penicillin for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease, mild to moderate:</i>
<b>Oral:</b> 1 g as a single dose in combination with IM cefoxitin as a single dose plus doxycycline and metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990253"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function </b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Cidofovir nephrotoxicity, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> No dosage adjustment of probenecid likely necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9951427','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9951427','lexi-content-ref-Expert.DOR'])">Ref</a></span>). <b>Note:</b> The use and dose of cidofovir in patients with kidney dysfunction should be evaluated separately.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Hyperuricemia, gout prevention: Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">eGFR ≥30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: The use of alternative agents is recommended due to reduced efficacy of probenecid in patients with eGFR &lt;60 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-Expert.DOR'])">Ref</a></span>). If use of probenecid is deemed appropriate, no dosage adjustment likely necessary; however, use with caution and frequent monitoring for safety and efficacy. Limited data demonstrate urate-lowering capability of probenecid in patients with eGFR 30 to 60 mL/minute/1.73 m<sup>2</sup> without increased risk of toxicity; however, robust evidence is lacking, and better alternatives are often available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29386212','lexi-content-ref-23457380','lexi-content-ref-21285173','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29386212','lexi-content-ref-23457380','lexi-content-ref-21285173','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sexually transmitted infections, as a pharmacokinetic enhancer to prolong beta-lactam serum levels: Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> No dosage adjustment is necessary for single dose probenecid regimens (ie, used in combination with cefoxitin for gonococcal infection or pelvic inflammatory disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Since probenecid may have limited efficacy in reducing the renal clearance of beta-lactam concentrations (ie, procaine penicillin) in patients with kidney impairment, the use of probenecid in combination with procaine penicillin for the treatment of neurosyphilis should be avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b>
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987416"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F213380"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatitis, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, gingival pain, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, aplastic anemia, hemolytic anemia, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache, pain (costovertebral)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, nephrotic syndrome, renal colic</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, severe hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F213395"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to probenecid or any component of the formulation; blood dyscrasias; uric acid kidney stones; children &lt;2 years of age; initiation during an acute gout attack.</p></div>
<div class="block war drugH1Div" id="F213377"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reaction: Has been associated with rare, severe hypersensitivity reactions, including anaphylaxis. Discontinue therapy if reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: May cause exacerbation of acute gouty attack.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• G6PD deficiency: Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: May not be effective in patients with kidney impairment; use with caution (ACR [FitzGerald 2020]; manufacturer’s labeling).</p></div>
<div class="block foc drugH1Div" id="F213388"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p></div>
<div class="block geq drugH1Div" id="F213373"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F213397"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Probenecid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.98 - $3.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613670"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or antacids to minimize GI effects</p></div>
<div class="block adm drugH1Div" id="F213392"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer with food to minimize GI effects. Maintain adequate fluid intake.</p></div>
<div class="block sts drugH1Div" id="F13108715"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).  Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568506"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Adjuvant to therapy with penicillins to prolong serum concentrations (FDA approved in ages ≥2 years and adults); treatment of hyperuricemia associated with gout and gouty arthritis (FDA approved in adults); has also been used with cephalosporin therapy to prolong serum concentrations and to prevent nephrotoxicity associated with cidofovir therapy </p></div>
<div class="block mst drugH1Div" id="F213449"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Probenecid may be confused with Procanbid</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F213438"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> MRP2, OAT1/3, UGT1A4, UGT1A6</p></div>
<div class="block dri drugH1Div" id="F213382"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.  Management: Consider limiting acetaminophen use in combination with probenecid. Probenecid may reduce clearance of acetaminophen to one of its non-toxic metabolities, increasing the risk for acetaminophen toxicity, even a lower doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagliptin: Probenecid may increase the serum concentration of Anagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avibactam: Probenecid may increase the serum concentration of Avibactam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Probenecid may increase the serum concentration of Baricitinib.  Management: When baricitinib is combined with probenecid, reduce baricitinib 4 mg daily to 2 mg daily or reduce baricitinib 2 mg daily to 1 mg daily. Don't use probenecid if recommended baricitinib dose is only 1 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betalactamase Inhibitors: Probenecid may increase the serum concentration of Betalactamase Inhibitors.  Management: Coadministration of probenecid with amoxicillin/clavulanate is not recommended per official package labeling.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefotaxime: Probenecid may increase the serum concentration of Cefotaxime.  Management: Avoid cefotaxime doses greater than 6 grams per day with concurrent probenecid. Any patients receiving this combination should be monitored for evidence of cefotaxime toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins: Probenecid may increase the serum concentration of Cephalosporins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: Probenecid may increase the serum concentration of Dexketoprofen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doripenem: Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dyphylline: Probenecid may increase the serum concentration of Dyphylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ertapenem: Probenecid may increase the serum concentration of Ertapenem. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemifloxacin: Probenecid may increase the serum concentration of Gemifloxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipenem: Probenecid may increase the serum concentration of Imipenem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoprofen: Probenecid may increase the serum concentration of Ketoprofen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Nasal): Probenecid may increase the serum concentration of Ketorolac (Nasal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketorolac (Systemic): Probenecid may increase the serum concentration of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LORazepam: Probenecid may increase the serum concentration of LORazepam.  Management: Reduce lorazepam dose 50% during coadministration with probenecid. Monitor for increased and prolonged lorazepam effects, particularly CNS depressant effects. Patients using lorazepam ER capsules should be switched to lorazepam tablets.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meropenem: Probenecid may increase the serum concentration of Meropenem. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Probenecid may increase the serum concentration of Methotrexate.  Management: If possible, the concomitant use of methotrexate and probenecid should be avoided. If used concomitantly, monitor closely for increased methotrexate serum concentrations and toxicities. Methotrexate dose reductions may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minoxidil (Systemic): Probenecid may increase the serum concentration of Minoxidil (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Probenecid may increase the serum concentration of Mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrofurantoin: Probenecid may diminish the therapeutic effect of Nitrofurantoin. Probenecid may increase the serum concentration of Nitrofurantoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oseltamivir: Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Probenecid may increase the serum concentration of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: UGT1A4 Inhibitors may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenprocoumon [INT]: Probenecid may decrease the serum concentration of Phenprocoumon [INT]. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PRALAtrexate: Probenecid may increase the serum concentration of PRALAtrexate.  Management: Avoid coadministration of pralatrexate with probenecid. If coadministration cannot be avoided, closely monitor for increased pralatrexate serum concentrations or possible toxicity with concomitant use of probenecid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Probenecid may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, accetaminophen exposure may be increased.  Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite.  Management: Consider limiting the use of propacetamide in patients who are also taking probenecid.  Patients may be at an increased risk for toxicity, even if reduced propacetamide doses are used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Probenecid may decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: Probenecid may increase the serum concentration of RifAMPin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Probenecid may increase the serum concentration of Roxadustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May diminish the therapeutic effect of Probenecid.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Probenecid may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulbactam: Probenecid may increase the serum concentration of Sulbactam.  Management: Recommendations for management of this interaction vary by specific sulbactam-containing product. Coadministration of probenecid with sulbactam/durlobactam is not recommended, but no specific actions are recommended for ampicillin/sulbactam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Probenecid may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Probenecid may increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Probenecid may increase the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F213398"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids.</p></div>
<div class="block pri drugH1Div" id="F13108713"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Probenecid crosses the placenta. Based on available data, an increased risk of adverse fetal events have not been reported (Gutman, 2012). </p></div>
<div class="block mopp drugH1Div" id="F53568491"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Uric acid, renal function, CBC</p></div>
<div class="block pha drugH1Div" id="F213376"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion</p></div>
<div class="block phk drugH1Div" id="F213394"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Effect on penicillin levels: 2 hours; Uric acid renal clearance: 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid and complete</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 85% to 95%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination (dose dependent): Normal renal function: 6 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 2 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F213399"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Benemid | Pro cid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Santuril</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Benemid | Probenecid biokanol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Probecid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Benemide | Probenecid biokanol | Santuril</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Probenid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bencid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Probenec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Benecid | Probenemid</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Benemid | Probenecid Weimer</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Benecid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Probecid</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Benemid | Benemide | Probenecid Weimer</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Benemid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Probenecid biokanol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Probecid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bencid | Benecid | Benemid | Proben</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Benemide</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Benemid | Brucid | Procid | Pronid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Santuril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Proben</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18307672">
<a name="18307672"></a>Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-Risk Adenovirus-Infected Pediatric Allogeneic Hematopoietic Progenitor Cell Transplant Recipients and Preemptive Cidofovir Therapy. <i>Pediatr Transplant</i>. 2008;12(2):219-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/18307672/pubmed" id="18307672" target="_blank">18307672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19392729">
<a name="19392729"></a>Bhadri VA, Lee-Horn L, Shaw PJ. Safety and Tolerability of Cidofovir in High-Risk Pediatric Patients. <i>Transpl Infect Dis</i>. 2009;11(4):373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/19392729/pubmed" id="19392729" target="_blank">19392729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9951427">
<a name="9951427"></a>Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. <i>Clin Pharmacol Ther</i>. 1999;65(1):21-28. doi:10.1016/S0009-9236(99)70118-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/9951427/pubmed" id="9951427" target="_blank">9951427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29386212">
<a name="29386212"></a>Case R, Wentworth B, Jester G. Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. <i>BMJ Case Rep</i>. 2018;2018:bcr2017222845. doi:10.1136/bcr-2017-222845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/29386212/pubmed" id="29386212" target="_blank">29386212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16157264">
<a name="16157264"></a>Cesaro S, Zhou X, Manzardo C, et al. Cidofovir for Cytomegalovirus Reactivation in Pediatric Patients After Hematopoietic Stem Cell Transplantation. <i>J Clin Virol</i>. 2005;34(2):129-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/16157264/pubmed" id="16157264" target="_blank">16157264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17845926">
<a name="17845926"></a>Doan ML, Mallory GB, Kaplan SL, et al. Treatment of Adenovirus Pneumonia With Cidofovir in Pediatric Lung Transplant Recipients. <i>J Heart Lung Transplant</i>. 2007;26(9):883-889.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/17845926/pubmed" id="17845926" target="_blank">17845926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22321288">
<a name="22321288"></a>Gutman J, Kachur SP, Slutsker L, et al. Combination of Probenecid-Sulphadoxine-Pyrimethamine for intermittent Preventive Treatment in Pregnancy. <i>Malar J</i>. 2012;11:39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/22321288/pubmed" id="22321288" target="_blank">22321288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17522099">
<a name="17522099"></a>Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. <i>Rheumatology (Oxford)</i>. 2007;46(8):1372-4. Available at http://rheumatology.oxfordjournals.org/content/suppl/2008/02/21/kem056a.DC1/kem056b.pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/17522099/pubmed" id="17522099" target="_blank">17522099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16551765">
<a name="16551765"></a>Ilett KF, Hackett LP, Ingle B, et al, “Transfer of Probenecid and Cephalexin into Breast Milk,” <i>Ann Pharmacother</i>, 2006, 40(5):986-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/16551765/pubmed" id="16551765" target="_blank">16551765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9502489">
<a name="9502489"></a>LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. <i>Clin Infect Dis</i>. 1998;26(2):512-513. doi:10.1086/517101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/9502489/pubmed" id="9502489" target="_blank">9502489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30403300">
<a name="30403300"></a>Permpalung N, Mahoney MV, Alonso CD. Adjunctive use of cidofovir and intravenous immunoglobulin to treat invasive adenoviral disease in solid organ transplant recipients. <i>Pharmacotherapy</i>. 2018;38(12):1260-1266. doi:10.1002/phar.2194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/30403300/pubmed" id="30403300" target="_blank">30403300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Probenecid.1">
<a name="Probenecid.1"></a>Probenecid tablet [prescribing information]. Philadelphia, PA: Lannett Company Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23457380">
<a name="23457380"></a>Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. <i>J Rheumatol</i>. 2013;40(6):872-876. doi:10.3899/jrheum.121301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/23457380/pubmed" id="23457380" target="_blank">23457380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21285173">
<a name="21285173"></a>Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. <i>J Rheumatol</i>. 2011;38(5):904-910. doi:10.3899/jrheum.101160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/21285173/pubmed" id="21285173" target="_blank">21285173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-hhs.1">
<a name="hhs.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated May 26, 2020. Accessed January 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vistide.1">
<a name="Vistide.1"></a>Vistide (cidofovir) [prescribing information]. Foster City, CA: Gilead; September 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19801951">
<a name="19801951"></a>Williams KM, Agwu AL, Dabb AA, et al, "A Clinical Algorithm Identifies High Risk Pediatric Oncology and Bone Marrow Transplant Patients Likely to Benefit From Treatment of Adenoviral infection," <i>J Pediatr Hematol Oncol</i>, 2009, 31(11):825-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/19801951/pubmed" id="19801951" target="_blank">19801951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16732176">
<a name="16732176"></a>Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. <i>Transplantation</i>. 2006;81(10):1398-1404.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/16732176/pubmed" id="16732176" target="_blank">16732176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16707532">
<a name="16707532"></a>Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/probenecid-pediatric-drug-information/abstract-text/16707532/pubmed" id="16707532" target="_blank">16707532</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12730 Version 190.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
